+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

The world's largest drugmaker thinks it has 11 billion-dollar drugs in the pipeline - here's what they treat

Aug 25, 2024, 21:44 IST
Jonathan Ernst/ReutersJohnson & Johnson just listed out the drugs it plans to file for approval over the next few years that could be "blockbusters."

These are drugs that haven't been approved yet, but by 2021, they could be making more than $1 billion in annual sales each.

Right now, the world's largest drugmaker is known for its immunology drugs like Remicade, which made $4.8 billion in sales in 2016 and Stelara, as well as the bloodthinner Xarelto, which made $2.2 billion in sales in 2016.

Here's the list of drugs J&J plans to file for approval over the next four years that could hit that blockbuster threshold, including cancer and depression treatments:

  • guselkumab - psoriasis (Filed for approval in 2016)
  • sirukumab - rheumatoid arthritis (Filed for approval in 2016)
  • apalutamide - pre-metastatic prostate cancer
  • esketamine - treatment-resistant depression
  • talacotuzumab - acute myeloid leukemia, a type of blood cancer
  • erdafitinib - solid tumors
  • niraparib - prostate cancer
  • imetelstat - myelofibrosis, a bone marrow disorder
  • pimodivir - influenza A
  • lumicitabine - respiratory syncytial virus (RSV) infection
  • JNJ-7922 - adjunctive treatment for major depressive disorder

More from Lydia Ramsey:

NOW WATCH: Trump is reportedly selling his Caribbean estate for $28 million - take a look inside

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article